Edwards Lifesciences affirms FY26 EPS view of $2.95-$3.05, consensus $3.01
Narrows higher FY26...
Story updates
08:24:00 PM UTC
SquawkNews
EW Q2 EPS $0.78 vs. est. $0.74; Q2 revs $1.74B vs. est. $1.7B; Q2 TAVR sales rose 11.3% Y/y to $1.3B; guides Q3 EPS $0.71-$0.77 vs. est. $0.75 and revs $1.63B-$1.71B vs. est. $1.69B; Narrows higher FY26 revenue growth view to 10%-11% from 9%-11%; affirms FY26 EPS view of $2.95-$3.05 vs. consensus $3.01; shares +7.8%
EW Q2 EPS $0.78 vs. est. $0.74; Q2 revs $1.74B vs. est. $1.7B; Q2 TAVR sales rose 11.3% Y/y to $1.3B; guides Q3 EPS $0.71-$0.77 vs. est. $0.75 and revs $1.63B-$1.71B vs. est. $1.69B; Narrows higher FY26 revenue growth view to 10%-11% from 9%-11%; affirms FY26 EPS view of $2.95-$3.05 vs. consensus $3.01; shares +7.8%